Association of PPP2R1A with Alzheimer's disease and specific cognitive domains

United Kingdom Brain Expression Consortium, PREVENT-AD Research Group

Research output: Contribution to journalArticle

Abstract

In an attempt to identify novel genetic variants associated with sporadic Alzheimer's disease (AD), a genome-wide association study was performed on a population isolate from Eastern Canada, referred to as the Québec Founder Population (QFP). In the QFP cohort, the rs10406151 C variant on chromosome 19 is associated with higher AD risk and younger age at AD onset in APOE4− individuals. After surveying the region surrounding this intergenic polymorphism for brain cis-eQTL associations in BRAINEAC, we identified PPP2R1A as the most likely target gene modulated by the rs10406151 C variant. PPP2R1A mRNA and protein levels are elevated in multiple regions from QFP autopsy-confirmed AD brains when compared with age-matched controls. Using an independent cohort of cognitively normal individuals with a parental history of AD, we found that the rs10406151 C variant is significantly associated with lower visuospatial and constructional performances. The association of the rs10406151 C variant with AD risk appears to involve brain PPP2R1A gene expression alterations. However, the exact pathological pathway by which this variant modulates AD remains elusive.

Original languageEnglish (US)
Pages (from-to)234-243
Number of pages10
JournalNeurobiology of Aging
Volume81
DOIs
StatePublished - Sep 1 2019

Fingerprint

Alzheimer Disease
Population
Brain
Chromosomes, Human, Pair 19
Intergenic DNA
Genome-Wide Association Study
Canada
Autopsy
Gene Expression
Messenger RNA
Genes
Proteins

Keywords

  • Alzheimer's disease
  • APOE4
  • Genome-wide association study
  • PPP2R1A
  • Quebec Founder Population
  • Visuospatial performance

ASJC Scopus subject areas

  • Neuroscience(all)
  • Aging
  • Clinical Neurology
  • Developmental Biology
  • Geriatrics and Gerontology

Cite this

Association of PPP2R1A with Alzheimer's disease and specific cognitive domains. / United Kingdom Brain Expression Consortium; PREVENT-AD Research Group.

In: Neurobiology of Aging, Vol. 81, 01.09.2019, p. 234-243.

Research output: Contribution to journalArticle

United Kingdom Brain Expression Consortium & PREVENT-AD Research Group 2019, 'Association of PPP2R1A with Alzheimer's disease and specific cognitive domains', Neurobiology of Aging, vol. 81, pp. 234-243. https://doi.org/10.1016/j.neurobiolaging.2019.06.008
United Kingdom Brain Expression Consortium ; PREVENT-AD Research Group. / Association of PPP2R1A with Alzheimer's disease and specific cognitive domains. In: Neurobiology of Aging. 2019 ; Vol. 81. pp. 234-243.
@article{b37a5ee34d794620af6cacff085eb366,
title = "Association of PPP2R1A with Alzheimer's disease and specific cognitive domains",
abstract = "In an attempt to identify novel genetic variants associated with sporadic Alzheimer's disease (AD), a genome-wide association study was performed on a population isolate from Eastern Canada, referred to as the Qu{\'e}bec Founder Population (QFP). In the QFP cohort, the rs10406151 C variant on chromosome 19 is associated with higher AD risk and younger age at AD onset in APOE4− individuals. After surveying the region surrounding this intergenic polymorphism for brain cis-eQTL associations in BRAINEAC, we identified PPP2R1A as the most likely target gene modulated by the rs10406151 C variant. PPP2R1A mRNA and protein levels are elevated in multiple regions from QFP autopsy-confirmed AD brains when compared with age-matched controls. Using an independent cohort of cognitively normal individuals with a parental history of AD, we found that the rs10406151 C variant is significantly associated with lower visuospatial and constructional performances. The association of the rs10406151 C variant with AD risk appears to involve brain PPP2R1A gene expression alterations. However, the exact pathological pathway by which this variant modulates AD remains elusive.",
keywords = "Alzheimer's disease, APOE4, Genome-wide association study, PPP2R1A, Quebec Founder Population, Visuospatial performance",
author = "{United Kingdom Brain Expression Consortium} and {PREVENT-AD Research Group} and Justin Miron and Cynthia Picard and Anne Labont{\'e} and Daniel Auld and Breitner, {John C.S.} and Judes Poirier",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.neurobiolaging.2019.06.008",
language = "English (US)",
volume = "81",
pages = "234--243",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Association of PPP2R1A with Alzheimer's disease and specific cognitive domains

AU - United Kingdom Brain Expression Consortium

AU - PREVENT-AD Research Group

AU - Miron, Justin

AU - Picard, Cynthia

AU - Labonté, Anne

AU - Auld, Daniel

AU - Breitner, John C.S.

AU - Poirier, Judes

PY - 2019/9/1

Y1 - 2019/9/1

N2 - In an attempt to identify novel genetic variants associated with sporadic Alzheimer's disease (AD), a genome-wide association study was performed on a population isolate from Eastern Canada, referred to as the Québec Founder Population (QFP). In the QFP cohort, the rs10406151 C variant on chromosome 19 is associated with higher AD risk and younger age at AD onset in APOE4− individuals. After surveying the region surrounding this intergenic polymorphism for brain cis-eQTL associations in BRAINEAC, we identified PPP2R1A as the most likely target gene modulated by the rs10406151 C variant. PPP2R1A mRNA and protein levels are elevated in multiple regions from QFP autopsy-confirmed AD brains when compared with age-matched controls. Using an independent cohort of cognitively normal individuals with a parental history of AD, we found that the rs10406151 C variant is significantly associated with lower visuospatial and constructional performances. The association of the rs10406151 C variant with AD risk appears to involve brain PPP2R1A gene expression alterations. However, the exact pathological pathway by which this variant modulates AD remains elusive.

AB - In an attempt to identify novel genetic variants associated with sporadic Alzheimer's disease (AD), a genome-wide association study was performed on a population isolate from Eastern Canada, referred to as the Québec Founder Population (QFP). In the QFP cohort, the rs10406151 C variant on chromosome 19 is associated with higher AD risk and younger age at AD onset in APOE4− individuals. After surveying the region surrounding this intergenic polymorphism for brain cis-eQTL associations in BRAINEAC, we identified PPP2R1A as the most likely target gene modulated by the rs10406151 C variant. PPP2R1A mRNA and protein levels are elevated in multiple regions from QFP autopsy-confirmed AD brains when compared with age-matched controls. Using an independent cohort of cognitively normal individuals with a parental history of AD, we found that the rs10406151 C variant is significantly associated with lower visuospatial and constructional performances. The association of the rs10406151 C variant with AD risk appears to involve brain PPP2R1A gene expression alterations. However, the exact pathological pathway by which this variant modulates AD remains elusive.

KW - Alzheimer's disease

KW - APOE4

KW - Genome-wide association study

KW - PPP2R1A

KW - Quebec Founder Population

KW - Visuospatial performance

UR - http://www.scopus.com/inward/record.url?scp=85069726045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069726045&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2019.06.008

DO - 10.1016/j.neurobiolaging.2019.06.008

M3 - Article

C2 - 31349112

AN - SCOPUS:85069726045

VL - 81

SP - 234

EP - 243

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

ER -